Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
3D models of heart failure… stiffened hearts in diabetes…. saving infant lives
After a heart attack, this peptide protects the heart from further injury
Featured Event
Heart Failure Symposium 2023
Virtual Library
Visit our YouTube channel filled with world-class heart failure educational sessions on diverse topics
ECHO Webinar: Tamer Mohamed (Aspect Biosystems): Mar 30 (11 am – 12 pm)
March 30, 2021 @ 11:00 am - 12:00 pm EDT
Please join us for an ECHO webinar on Tuesday Mar 30, 2021 (11 am – 12 pm) featuring Tamer Mohamed (President & CEO, Aspect Biosystems). Tamer’s presentation entitled, “From Research to Commercialization: The Aspect Biosystems Journey to Bioprinted Therapeutics”, will feature an overview of Aspect Biosystems, its technologies and the story behind its success. Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics.